Cleomiscosin ACAS# 76948-72-6 |
- 8'-Epicleomiscosin A
Catalog No.:BCC3917
CAS No.:
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 76948-72-6 | SDF | Download SDF |
PubChem ID | 335652 | Appearance | Powder |
Formula | C20H18O8 | M.Wt | 386.4 |
Type of Compound | Coumarins | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-5-methoxy-2,3-dihydropyrano[3,2-h][1,4]benzodioxin-9-one | ||
SMILES | COC1=C(C=CC(=C1)C2C(OC3=C4C(=CC(=C3O2)OC)C=CC(=O)O4)CO)O | ||
Standard InChIKey | OCBGWPJNUZMLCA-RDJZCZTQSA-N | ||
Standard InChI | InChI=1S/C20H18O8/c1-24-13-7-10(3-5-12(13)22)17-15(9-21)26-20-18-11(4-6-16(23)27-18)8-14(25-2)19(20)28-17/h3-8,15,17,21-22H,9H2,1-2H3/t15-,17-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Cleomiscosin A and brusatol are antitumor agents, have antileukemic principles. 2. Cleomiscosin A has antioxidant activity, it could be beneficial in preventing LDL oxidation in atherosclerotic lesions. 3. Cleomiscosin A methyl ether derivatives have anti-inflammatory activity. 4. Cleomiscosin A shows inhibitory activity to TNF-α secretion of the mouse peritoneal macrophages. 5. The mixture of three compounds (cleomiscosin A, B and C) is showing the significant protective effects against CCl(4)-induced hepatotoxicity in small animals and also coumarinolignoids are well tolerated by small animals in acute oral study. |
Targets | LDL | TNF-α |
Cleomiscosin A Dilution Calculator
Cleomiscosin A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.588 mL | 12.94 mL | 25.8799 mL | 51.7598 mL | 64.6998 mL |
5 mM | 0.5176 mL | 2.588 mL | 5.176 mL | 10.352 mL | 12.94 mL |
10 mM | 0.2588 mL | 1.294 mL | 2.588 mL | 5.176 mL | 6.47 mL |
50 mM | 0.0518 mL | 0.2588 mL | 0.5176 mL | 1.0352 mL | 1.294 mL |
100 mM | 0.0259 mL | 0.1294 mL | 0.2588 mL | 0.5176 mL | 0.647 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Onitin 2'-O-glucoside
Catalog No.:BCN4319
CAS No.:76947-60-9
- 8-Bromo-cAMP, sodium salt
Catalog No.:BCC8078
CAS No.:76939-46-3
- Viscosalactone B
Catalog No.:BCN7945
CAS No.:76938-46-0
- Begacestat
Catalog No.:BCC2346
CAS No.:769169-27-9
- 13-Methyl-8,11,13-podocarpatriene-3,12-diol
Catalog No.:BCN1360
CAS No.:769140-74-1
- Triacsin C
Catalog No.:BCC7377
CAS No.:76896-80-5
- Bz-Gly-OH.HCl
Catalog No.:BCC2945
CAS No.:7689-50-1
- Camptothecin
Catalog No.:BCN4318
CAS No.:7689-03-4
- Olivil 4'-O-glucoside
Catalog No.:BCN7557
CAS No.:76880-93-8
- 8-Methyl-8-azabicyclo[3.2.1]octane-3,6-diol, 9CI; (3RS,6RS)-form, 3-O-Ac
Catalog No.:BCN1361
CAS No.:7688-76-8
- 6-Hydroxywogonin
Catalog No.:BCN6556
CAS No.:76844-70-7
- Przewaquinone A
Catalog No.:BCN3004
CAS No.:76843-23-7
- DL-alpha-Tocopherylacetate
Catalog No.:BCN2904
CAS No.:7695-91-2
- Kalii Dehydrographolidi Succinas
Catalog No.:BCN8523
CAS No.:76958-99-1
- Nizatidine
Catalog No.:BCC4522
CAS No.:76963-41-2
- H-D-2-Nal-OH.HCl
Catalog No.:BCC3286
CAS No.:76985-09-6
- Boc-D-2-Nal-OH
Catalog No.:BCC3288
CAS No.:76985-10-9
- Cleomiscosin B
Catalog No.:BCN3898
CAS No.:76985-93-8
- TPT-260
Catalog No.:BCC5171
CAS No.:769856-81-7
- 15-Methoxypinusolidic acid
Catalog No.:BCN4321
CAS No.:769928-72-5
- Notoginsenoside T5
Catalog No.:BCN3727
CAS No.:769932-34-5
- Euphroside
Catalog No.:BCN6633
CAS No.:76994-07-5
- Garcinone C
Catalog No.:BCN4322
CAS No.:76996-27-5
- Gibberellins
Catalog No.:BCN2189
CAS No.:77-06-5
Synthesis and anti-inflammatory activity of derivatives of coumarino-lignoid, cleomiscosin A and its methyl ether.[Pubmed:20813432]
Eur J Med Chem. 2010 Nov;45(11):5150-6.
Six novel Cleomiscosin A (a coumarino-lignoid), derivatives have been synthesized for the first time by using electrophilic substitution reaction to give nuclear nitrated and halogenated derivatives of Cleomiscosin A in good yields. Structures of these compounds were established on the basis of IR, (1)H NMR, (13)C NMR and Mass spectral data. Some of the synthesized derivatives were tested for in-vitro target based anti-inflammatory study using primary macrophages cell culture bioassay system. The results showed that the compounds 1a, 3a and 4a (1 and 10 mug/mL) exhibited potent anti-inflammatory activity.
QSAR, docking and in vitro studies for anti-inflammatory activity of cleomiscosin A methyl ether derivatives.[Pubmed:23022518]
Eur J Pharm Sci. 2012 Dec 18;47(5):952-64.
A series of five (6a-8b) novel polyhalogenated derivatives and an interesting ester (9a) derivative have been synthesized from Cleomiscosin A methyl ether. All the six derivatives were subjected to in silico QSAR modeling and docking studies and later the predicted results were confirmed through in vitro experiments. QSAR modeling results showed that compounds 6a and 9a possessed anti-inflammatory activity comparable or even higher than diclofenac sodium. Docking results revealed that compounds 9a and 6a showed very good anti-inflammatory activity due to low docking energies of viz., IL6 (-92.45 and -81.993 kcal mol(-1)), TNF-alpha (-94.992 and -69.235 kcal mol(-1)) and IL1beta (-67.462 and -65.985 kcal mol(-1)). Further all the six novel derivatives were subjected for in vitro anti-inflammatory activity using primary macrophages cell culture bioassay system. At the initial doses of 1 mug/ml and 10 mug/ml, the pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) were quantified from cell culture supernatant using enzyme linked immunosorbent assay (ELISA). The in vitro effect of 6a-9a on cell viability in mouse peritoneal macrophage cells isolated from mice was evaluated using MTT assay. The in silico and in vitro data suggested that all the derivatives might be considered as potential anti-inflammatory drug-like molecules.
Antioxidant activity of cleomiscosins A and C isolated from Acer okamotoanum.[Pubmed:17424931]
Arch Pharm Res. 2007 Mar;30(3):275-81.
Phytochemical investigation of Acer okamotoanum leaf and twig led to the isolation of two coumarinolignans, Cleomiscosin A (1) and cleomiscosin C (2). Here, we found that 2 dose-dependently inhibits LDL oxidation mediated by either catalytic copper ions (Cu2+) or free radicals generated with the azo compound 2,2'-azobis-(2-amidinopropane)dihydro-chloride (AAPH) with IC50s of 29.5 and 11.9 microM, respectively. By electrophoretic analysis, we also observed that 2 protects apolipoprotein B-100 (apoB-100) against Cu2+-induced fragmentation (65.3% inhibition at 5 microM). Furthermore, fluorescence analyses clearly indicated that both 1 and 2 protect against the oxidative modification of apoB-100 induced by either Cu2+ or HOCl (1, IC50s of 13.4 and 8.1 microM, respectively; 2, IC50s of 23.6 and 3.9 microM, respectively). These findings suggest that 1 and 2 could be beneficial in preventing LDL oxidation in atherosclerotic lesions.
Hepatoprotective Effects and Safety Evaluation of Coumarinolignoids Isolated from Cleome viscosa Seeds.[Pubmed:21969749]
Indian J Pharm Sci. 2010 Nov;72(6):759-65.
The aim of the present work was to investigate the in vivo hepatoprotective potential of coumarinolignoids (cleomiscosins A, B, and C) isolated from the seeds of C. viscosa. The study was performed against CCl(4)-induced hepatotoxicity in albino rats. Rats were divided into four groups. The animals of group I served as normal and was given only vehicle. Group II served as toxin control and administered with CCl(4) (50% solution liquid paraffin, 2 ml/kg intraperitoneally). The animals of group III received coumarinolignoids (50 mg/kg) for six days orally as well as CCl(4) (2 ml/kg) on 4(th) day i.p. Similarly animals of group IV received silymarin (50 mg/kg) for six days orally as well as CCl(4) on 4(th) day i.p. On 7(th) day various parameters viz. serum glutamyl oxaloacetic transaminase, serum glutamyl pyruvate transaminase, serum alkaline phosphatase, serum bilirubin, liver glycogen were estimated and histopathology was performed. Additionally, acute oral toxicity of the said coumarinolignoids was carried out in swiss albino mice. The coumarinolignoids were found to be effective as hepatoprotective against CCl(4)-induced hepatotoxicity as evidenced by in vivo and histopathological studies in small animals. Safety evaluation studies also exhibit that coumarinolignoids are well tolerated by small animals in acute oral toxicity study except minor changes in red blood cell count and hepatic protein content at 5000 mg/kg body weight as a single oral dose. Coumarinolignoids which is the mixture of three compounds (Cleomiscosin A, B and C) is showing the significant protective effects against CCl(4)-induced hepatotoxicity in small animals and also coumarinolignoids are well tolerated by small animals in acute oral study.
[Chemical constituents from branch of Macaranga adenantha and their TNF-alpha inhibitory activity].[Pubmed:17802880]
Zhongguo Zhong Yao Za Zhi. 2007 Jun;32(12):1175-9.
OBJECTIVE: To investigate the chemical constituents of the brach of Macaranga adenantha, and evaluate their TNF-alpha inhibitory activity. METHOD: The chemical conshifuents were isolated and purified by chromatographic methods. Structures of the compounds were identified by spectroscopic methods. The TNF-alpha secretion inhibitory activity of the mouse peritoneal macrophages was evaluated by MTT methods. RESULT: Ten compounds were isolated and their structures were identified as: Cleomiscosin A (1), cleomiscosin B (2), ellagic acid 4-O-alpha-D-rhamnopyranside (3), ellagic acid 4-O-beta-D-xylopyranoside (4), vanillic acid (5), (24R) -stigmast-4-en-3-one (6), (24R) -stigmast-3, 6-dione (7), (24R) -6beta-hydroxy-stigmast-4-en-3-one (8), daucosterol (9), beta-sitosteryl glucoside-6'-O-heptadecoicate (10). At a concentration of 10 micromol x L(-1), compounds 1, 3 and 4 showed inhibitory activity to TNF-alpha secretion of the mouse peritoneal macrophages with the inhibitory rates of 57.0%, 64.4%, and 57. 4%, respectively. CONCLUSION: All compounds were isolated from genus Macaranga for the first time. Compounds 1, 3, and 4 were active against TNF-alpha secretion of the mouse peritoneal macrophages.